Immune Manifestations with Checkpoint Inhibitors in a Single Brazilian Center: Experience and Literature Review

• DOI: 10.2144/fsoa-2020-0129
• Publication Date: 2020-11-23T14:45:48Z
• Authors: Rafael A Schmerling; Antonio C Buzaid; Carolina K Haddad; Fabio AB Schutz; Fabio R Kater; Juliana Pimenta; Fernando Maluf; William N William; Camila Lopes; Dafne R Bromberg; Ana C Oliveira; Ricardo Golmia; Morton Scheinberg
• Keywords: tumor; Medicine (General); Short Communication; malignant melanoma; R; autoimmune disease; 3. Good health; 03 medical and health sciences; endocrine system; R5-920; 0302 clinical medicine; Medicine; immunotherapy; checkpoint inhibitors

The presence of autoimmune events were recorded in patients receiving immune checkpoint inhibitors.Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012-2019.A total of 554 patients received ICIs of which 123 developed an immune related adverse event. Twenty one (17%) with toxicity were identified as having a pre-existing autoimmune disease and 88 required treatment with corticosteroids or hormone replacement. Thirty two (26%) out of 123 had to temporarily discontinue ICIs due to autoimmune manifestations. Endocrine and skin manifestations were the most prevalent immune disorders in our cohort. In melanoma better efficacy was seen in patients with immune toxicity.Autoimmune diseases appear in patients receiving ICIs in this real world experience. Our results differ from other series on the frequency of autoimmunity. Complete discontinuation of ICIs due to autoimmunity was rare.